SCHEMBL23354524

SCHEMBL23354524

COC(=O)c1ccccc1-c1ccc(C(C)(F)F)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.68
SLC6A4 P31645 3/20 0.68
SLC6A2 P23975 1/20 0.56
BRS3 P32247 1/20 0.47
ROCK2 O75116 1/20 0.47
CSF1R P07333 1/20 0.47
KDR P35968 1/20 0.47
FLT3 P36888 1/20 0.47
GSK3A P49840 1/20 0.47
GSK3B P49841 1/20 0.47
CDK5 Q00535 1/20 0.47
ROCK1 Q13464 1/20 0.47
SLK Q9H2G2 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
PDK2 Q15119 2/20 0.47
SDHB P21912 1/20 0.46
BDKRB1 P46663 3/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31676838 1.00 SLC6A3 (0.68) SLC6A3SLC6A4SLC6A2BRS3ROCK2
SCHEMBL10645473 0.89 SLC6A3 (0.69) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL29979725 0.89 SLC6A3 (0.69) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL23354401 0.88 SLC6A3 (0.64) SLC6A3SLC6A4SLC6A2BRS3ROCK2
SCHEMBL29979219 0.88 SLC6A3 (0.64) SLC6A3SLC6A4SLC6A2BRS3ROCK2
SCHEMBL29979412 0.88 SLC6A3 (0.67) SLC6A3SLC6A4SLC6A2BRS3ROCK2
SCHEMBL23354290 0.88 SLC6A3 (0.67) SLC6A3SLC6A4SLC6A2BRS3ROCK2
SCHEMBL23354286 0.84 SLC6A3 (0.62) SLC6A3SLC6A4SLC6A2BRS3ROCK2
SCHEMBL29979533 0.84 SLC6A3 (0.62) SLC6A3SLC6A4SLC6A2BRS3ROCK2
SCHEMBL18997885 0.84 PDK2 (0.50) SLC6A3SLC6A4SLC6A2BRS3PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 SLC6A3 1469/4885SLC6A4 1821/4885SLC6A2 3380/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 SLC6A3 1469/4885SLC6A4 1821/4885SLC6A2 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.